Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Dengue virus type 4 structural proteins** are composed of three distinct proteins—**capsid (C) protein**, **premembrane/membrane (prM/M) protein**, and **envelope (E) protein**, encoded by the viral genome as part of a single polyprotein. The **C protein** (∼12 kDa) forms homodimers and binds both viral RNA and lipid membranes, assembling the viral nucleocapsid[1][2][4]. The **prM/M protein** is essential for virion maturation, protecting E during assembly, and, upon cleavage, transitioning the immature virus to a mature, infectious state[3][6]. The **E protein** is the main surface glycoprotein responsible for attachment and entry into host cells, and contains domains for receptor binding, membrane fusion, and is the primary target of neutralizing antibodies[5]. Together, these proteins are essential for the formation, maturation, and infectivity of the virus and serve as key molecular targets for antiviral strategies and vaccine development[3][5][6].
Monoclonal antibodies: neutralization of virus by binding to E protein and blocking attachment, fusion, or uncoating[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus type 4 structural protein (capsid protein, prM protein, envelope protein).